MXPA05010597A - Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. - Google Patents

Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.

Info

Publication number
MXPA05010597A
MXPA05010597A MXPA05010597A MXPA05010597A MXPA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A MX PA05010597 A MXPA05010597 A MX PA05010597A
Authority
MX
Mexico
Prior art keywords
breast cancer
hydroxy tamoxifen
prevention
treatment
patients
Prior art date
Application number
MXPA05010597A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Rouanet
Original Assignee
Lab Besins Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Besins Internat filed Critical Lab Besins Internat
Publication of MXPA05010597A publication Critical patent/MXPA05010597A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MXPA05010597A 2003-04-01 2003-12-15 Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi. MXPA05010597A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
MXPA05010597A true MXPA05010597A (es) 2006-03-09

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010597A MXPA05010597A (es) 2003-04-01 2003-12-15 Prevencion y tratamiento de cancer de mama con tamoxifen 4-hidroxi.

Country Status (11)

Country Link
US (2) US7704516B2 (enExample)
EP (3) EP1608353B1 (enExample)
JP (1) JP5490346B2 (enExample)
AU (1) AU2003294973B2 (enExample)
CA (1) CA2519980C (enExample)
ES (3) ES2483896T3 (enExample)
IL (1) IL170807A (enExample)
MX (1) MXPA05010597A (enExample)
NO (1) NO333805B1 (enExample)
NZ (1) NZ542499A (enExample)
WO (1) WO2004087123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
AU2005227072B2 (en) * 2004-03-22 2010-08-19 Besins Healthcare Luxembourg Sarl Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
CA2582174C (en) * 2004-10-14 2013-01-29 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
CN110044998B (zh) * 2014-05-12 2021-12-14 奎斯特诊断投资公司 通过质谱法定量他莫昔芬及其代谢物
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
WO2016094854A2 (en) * 2014-12-12 2016-06-16 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
JP2026525970A (ja) * 2023-07-19 2026-08-04 アトッサ・セラピューティクス・インコーポレイテッド 抗腫瘍化合物ならびにその使用方法及びその合成方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (enExample) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
AU2513899A (en) 1997-12-23 1999-07-19 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ATE290856T1 (de) 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
EP1317921B1 (fr) * 2001-12-07 2009-08-19 Besins International Belgique Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
ES2456957T3 (es) 2014-04-24
WO2004087123A1 (en) 2004-10-14
AU2003294973A1 (en) 2004-10-25
US8475814B2 (en) 2013-07-02
EP1941871B1 (en) 2014-01-08
NZ542499A (en) 2008-10-31
EP1952810A1 (en) 2008-08-06
HK1086193A1 (en) 2006-09-15
CA2519980A1 (en) 2004-10-14
JP5490346B2 (ja) 2014-05-14
ES2483896T3 (es) 2014-08-08
IL170807A (en) 2014-08-31
NO333805B1 (no) 2013-09-16
US7704516B2 (en) 2010-04-27
EP1952810B1 (en) 2014-01-08
NO20054526L (no) 2005-09-30
EP1608353A1 (en) 2005-12-28
EP1608353B1 (en) 2014-04-30
ES2456958T3 (es) 2014-04-24
US20090186944A1 (en) 2009-07-23
AU2003294973B2 (en) 2010-05-13
HK1119950A1 (en) 2009-03-20
JP2006514967A (ja) 2006-05-18
US20050031695A1 (en) 2005-02-10
CA2519980C (en) 2012-04-10
EP1941871A1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
US10758514B2 (en) Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
Berkson et al. Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
RU2012148710A (ru) Органическое соединение для применения при лечении рака печени
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
WO2002043720A3 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0606774A2 (pt) método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
EA201270298A1 (ru) Способ лечения злокачественной опухоли
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
PT1748770E (pt) Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno
Lee et al. Successful outcome of breast cancer patient refusing conventional treatments: A case report
US20140100174A1 (en) Treatment for Cancer
Baghi et al. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
Thorstad et al. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data
Nakashima et al. Selective (intra-arterial), rapid infusion chemo-radiotherapy to preserve the larynx in advanced laryngeal carcinoma: preliminary results
Starr Venetoclax Shows Strong Activity in CLL
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
van derBoon New drug slows prostate-cancer progression

Legal Events

Date Code Title Description
FG Grant or registration